Novel blood-based proteomic signatures across multiple neurodegenerative diseases.

ABSTRACT:

Introduction

Blood-based biomarkers have the potential to support early and accurate diagnoses of neurodegenerative diseases, which are sensitive to molecular pathology and are predictive of outcome. We evaluated a novel multiplex proteomic method in people with diverse neurodegenerative diseases.

Methods

Serum from people with Alzheimer's disease (N = 36), Lewy body dementia (N = 34), frontotemporal dementia (N = 36), and progressive supranuclear palsy (N = 36) and age-matched controls (N = 30) was analyzed with the nucleic acid linked immuno-sandwich assay (NULISA) central nervous system panel (≈ 120 analytes) and inflammation panel (250 analytes). Biomarkers were compared across groups and included as predictors of survival.

Results

The NULISA panels demonstrated h

SUBMITTER: Durcan R 

PROVIDER: S-EPMC11947754 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature